Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...

The test is designed to help pathologists differentiate ... The clearance follows the assay's CE Mark approval in June 2024. B-cell lymphoma is a type of cancer that typically develops in the ...

IDEXX will offer a new canine lymphoma test in the U.S. and Canada in late March. Shares of IDEXX Laboratories (IDXX) surged 10% to lead S&P 500 gainers Monday after the provider of veterinary ...

Doctors are enrolling patients in a groundbreaking clinical trial aimed at reducing cancer recurrence in patients with ...

1,2 The test helps differentiate a B-cell cancer from a normal, reactive immune response, offering diagnostic certainty for healthcare providers and their patients. B-cell lymphoma accounts for ...

Coulier recalls, “Three days later, my doctors called me back and they said, ‘We wish we had better news for you, but you have non-Hodgkin’s lymphoma ... his bone marrow test has come ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

"At an affordable price point, this test increases access to cancer diagnoses ... general practitioners can now provide a clinical diagnosis of lymphoma earlier than traditional diagnostics.

Roche (RHHBY) announced that it has received 510(k) clearance from the FDA for its highly-sensitive in-situ hybridisation test, the Ventana Kappa and Lambda Dual ISH mRNA Probe Cocktail.

IDEXX Laboratories exceeded fourth-quarter profit and revenue estimates on sales of its animal testing products and price increases.

The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is the first clinically approved in-situ hybridisation (ISH) test with the sensitivity to assess the full spectrum of B-cell lymphoma ...